INT10057

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 35
Total Number 35
Disease Relevance 23.99
Pain Relevance 3.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Ldlr) transport (Ldlr) aging (Ldlr)
plasma membrane (Ldlr) lipid metabolic process (Ldlr) lysosome (Ldlr)
Anatomy Link Frequency
neural 3
hepatocytes 2
liver 2
macrophages 1
Blood 1
Ldlr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Angina 68 99.28 Very High Very High Very High
alcohol 6 97.96 Very High Very High Very High
Nerve growth factor 3 97.10 Very High Very High Very High
fluoxetine 3 92.60 High High
Restless leg syndrome 24 91.16 High High
cytokine 6 88.08 High High
Inflammation 91 87.16 High High
anesthesia 2 87.04 High High
depression 3 75.44 Quite High
metalloproteinase 26 72.32 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 199 100.00 Very High Very High Very High
Microvascular Angina 10 99.84 Very High Very High Very High
Myocardial Infarction 67 99.76 Very High Very High Very High
Diabetes Mellitus 232 99.32 Very High Very High Very High
Hyperlipidemia 99 99.32 Very High Very High Very High
Acute Coronary Syndrome 31 99.20 Very High Very High Very High
Atherosclerosis 79 99.08 Very High Very High Very High
Metabolic Syndrome 4 98.72 Very High Very High Very High
Obesity 50 98.62 Very High Very High Very High
Hypertension 42 98.42 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Low density lipoprotein (LDL) apheresis was carried out in 28 atherosclerotic patients with clinical signs of poor peripheral circulation and abnormally high LDL levels.
Gene_expression (apheresis) of Low density lipoprotein associated with atherosclerosis
1) Confidence 0.67 Published 1992 Journal ASAIO J. Section Abstract Doc Link 1457897 Disease Relevance 0.66 Pain Relevance 0.12
Cuban studies claim that 1 to 20 mg/day of the original PC supplement are effective at producing significant reductions in total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C).
Gene_expression (producing) of low density lipoprotein cholesterol associated with disorder of lipid metabolism
2) Confidence 0.66 Published 2010 Journal Crit Rev Food Sci Nutr Section Abstract Doc Link 20301014 Disease Relevance 0.27 Pain Relevance 0.08
It is a acetylcholinesterase inhibitor similar to Galanthamine[9], a drug treating AD, and might be a low-molecular-weight neurotrophic drug to neurodegeneration disorder such as AD by potentiating the nerve growth factor (NGF)-induced differentiation in neural cells [10]; berberine is a novel cholesterol-lowering drug distinctly from statins by stabilizating the low density lipoprotein receptor (LDLR) mRNA to increase LDLR expression and inhibiting lipid synthesis[11,12].
Gene_expression (expression) of LDLR in neural associated with nerve growth factor and disease
3) Confidence 0.57 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1693919 Disease Relevance 0.92 Pain Relevance 0.19
It is a acetylcholinesterase inhibitor similar to Galanthamine[9], a drug treating AD, and might be a low-molecular-weight neurotrophic drug to neurodegeneration disorder such as AD by potentiating the nerve growth factor (NGF)-induced differentiation in neural cells [10]; berberine is a novel cholesterol-lowering drug distinctly from statins by stabilizating the low density lipoprotein receptor (LDLR) mRNA to increase LDLR expression and inhibiting lipid synthesis[11,12].
Gene_expression (expression) of LDLR in neural associated with nerve growth factor and disease
4) Confidence 0.50 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1693919 Disease Relevance 0.93 Pain Relevance 0.20
It is a acetylcholinesterase inhibitor similar to Galanthamine[9], a drug treating AD, and might be a low-molecular-weight neurotrophic drug to neurodegeneration disorder such as AD by potentiating the nerve growth factor (NGF)-induced differentiation in neural cells [10]; berberine is a novel cholesterol-lowering drug distinctly from statins by stabilizating the low density lipoprotein receptor (LDLR) mRNA to increase LDLR expression and inhibiting lipid synthesis[11,12].
Gene_expression (expression) of low density lipoprotein receptor in neural associated with nerve growth factor and disease
5) Confidence 0.50 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1693919 Disease Relevance 0.94 Pain Relevance 0.20
The plant stanol ester margarine Benecol® (Raisio Group, Raisio, Finland), launched in Finland in 1995, is an example of a functional food that has been shown to lower effectively serum total and LDL-cholesterol levels in several interventions [5,6].
Gene_expression (levels) of LDL-cholesterol
6) Confidence 0.45 Published 2005 Journal Nutr J Section Body Doc Link PMC1177987 Disease Relevance 0.21 Pain Relevance 0
In the Münster Heart Study (PROCAM), 8-year follow up of a cohort of middle-aged men has led to the identification of nine variables which independently contribute to CHD risk: age, smoking history, personal history of angina pectoris, family history of myocardial infarction (MI), presence of diabetes mellitus, systolic blood pressure and the levels of low density lipoprotein (LDL) cholesterol, high density lipoprotein cholesterol and triglyceride.
Gene_expression (levels) of low density lipoprotein in Heart associated with angina, nicotine addiction, coronary artery disease, diabetes mellitus and myocardial infarction
7) Confidence 0.43 Published 1998 Journal Eur. Heart J. Section Abstract Doc Link 9857944 Disease Relevance 1.04 Pain Relevance 0.10
At the end of 1 month of treatment, levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein cholesterol, triglycerides, and the total cholesterol:high-density lipoprotein (HDL) cholesterol and LDL:HDL cholesterol ratios were significantly lower and the HDL cholesterol levels were significantly higher.
Gene_expression (lower) of low-density lipoprotein associated with disorder of lipid metabolism
8) Confidence 0.40 Published 1992 Journal Clin Ther Section Abstract Doc Link 1638580 Disease Relevance 0.98 Pain Relevance 0.06
Intensive LDL-cholesterol reduction has the potential to improve endothelial function within hours [3] by reducing the production of superoxide anion within the vessel wall, thus facilitating the release of nitric oxide and slowing its rate of catabolism.
Gene_expression (reduction) of LDL-cholesterol
9) Confidence 0.34 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59635 Disease Relevance 0.63 Pain Relevance 0.12
Notwithstanding these limitations, there was no trend to suggest that atorvastatin treatment in MIRACL was of greater benefit in patients with higher baseline LDL-cholesterol levels.
Gene_expression (levels) of LDL-cholesterol
10) Confidence 0.34 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59635 Disease Relevance 0.24 Pain Relevance 0
Pravastatin 10-40 mg/day produced significant reductions (vs baseline or placebo) in serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in elderly patients (aged >or=60 or >or= 65 years) with hypercholesterolaemia or normal cholesterol levels.
Gene_expression (produced) of low-density lipoprotein cholesterol associated with hyperlipidemia and disorder of lipid metabolism
11) Confidence 0.31 Published 2003 Journal Drugs Aging Section Abstract Doc Link 14651445 Disease Relevance 0.35 Pain Relevance 0
LDL-c = Low Density Lipoprotein cholesterol
Gene_expression (cholesterol) of Low Density Lipoprotein
12) Confidence 0.30 Published 2007 Journal Lipids Health Dis Section Body Doc Link PMC1933532 Disease Relevance 0.96 Pain Relevance 0
A new therapeutic option for such patients is regular treatment with low density lipoprotein (LDL) apheresis.
Gene_expression (apheresis) of low density lipoprotein
13) Confidence 0.23 Published 2000 Journal Ther Apher Section Abstract Doc Link 10910023 Disease Relevance 0.54 Pain Relevance 0
Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
Gene_expression (apheresis) of Low density lipoprotein associated with hyperlipidemia
14) Confidence 0.23 Published 2000 Journal Ther Apher Section Title Doc Link 10910023 Disease Relevance 0.78 Pain Relevance 0.06
In conclusion, from the observation, the protective effect of the seeds of E. variegata on high fat induced hyperlipidemia may be attributed to a decrease in cholesterol synthesis, an increase in cholesterol excretion and expression of LDL receptor and subsequent catabolism.
Gene_expression (expression) of LDL receptor in fat associated with hyperlipidemia
15) Confidence 0.21 Published 2010 Journal Journal of Pharmacy and Bioallied Sciences Section Body Doc Link PMC2996074 Disease Relevance 0.26 Pain Relevance 0
Over the 5.4 years of median follow-up, simvastatin produced changes in total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol of -25%, -35%, and +8%, respectively, with minimal adverse effects.
Gene_expression (produced) of low density lipoprotein associated with disorder of lipid metabolism
16) Confidence 0.21 Published 1995 Journal Am. J. Cardiol. Section Abstract Doc Link 7572690 Disease Relevance 0.62 Pain Relevance 0.09
In order to study these effects, the impact of chronic mild stress (CMS) on rats, and of the subsequent administration of Banxia-houpu decoction and fluoxetine, were studied regarding their effects on the following biochemical parameters: 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in various brain regions, natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities in spleen, serum lipid profiles including total cholesterol (TC), high density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc) and triglyceride (TG), liver superoxide dismutase (SOD) and nitric oxide synthase (NOS) activities, serum malondialdehyde (MDA), and interleukin-2 (IL-2) levels.
Gene_expression (levels) of low density lipoprotein cholesterol in liver associated with stress, disorder of lipid metabolism and fluoxetine
17) Confidence 0.18 Published 2003 Journal Life Sci. Section Abstract Doc Link 14575813 Disease Relevance 0.90 Pain Relevance 0.20
100 mg/dL), moderate (LDL-cholesterol target of ?
Gene_expression (target) of LDL-cholesterol
18) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988621 Disease Relevance 0.16 Pain Relevance 0
The data fields extracted from charts were those used by NCEP guidelines to characterize risk for coronary events, for example, the presence of diabetes, history of angina, history of peripheral vascular disease, smoking, hypertension, according to a scale of high, moderate, or low risk and assignment to target levels of LDL-cholesterol ?
Gene_expression (levels) of LDL-cholesterol associated with angina, nicotine addiction, diabetes mellitus, hypertension and increased venous pressure under development
19) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988621 Disease Relevance 0.49 Pain Relevance 0.10
130 mg/dL), or low ( LDL-cholesterol target of ?
Gene_expression (target) of LDL-cholesterol
20) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988621 Disease Relevance 0.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox